<DOC>
	<DOCNO>NCT02914184</DOCNO>
	<brief_summary>The purpose study evaluate clinical consistency three production lot Porcine circovirus ( PCV ) -free liquid formulation oral live attenuate human rotavirus ( HRV ) vaccine evaluate PCV-free liquid formulation HRV vaccine compare currently license lyophilise formulation HRV vaccine term immunogenicity , reactogenicity safety administer two-dose vaccination healthy infant start age 6-12 week . No new subject enrol extension phase study</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Two Formulations GSK Biologicals ' Human Rotavirus ( HRV ) Vaccine ( 444563 ) , Healthy Infants Starting Age 6-12 Weeks</brief_title>
	<detailed_description>- Experimental design : Phase IIIA , observer-blind , randomise ( 1:1:1:1 ) , control , multi-centric , four parallel group stagger enrolment ( Part A Part B ) . - Duration study : The intended duration study , per subject , approximately 7-8 month include 6 month extend safety follow-up period last dose HRV vaccine . - Epoch 001 : Primary start Visit 1 ( Day 0 ) end safety follow-up contact ( Month 7-8 ) . - Primary completion Date ( PCD ) : Visit 3 ( Month 2-4 ) . - End Study ( EoS ) : Last testing result release sample collect Visit 3 Last Subject Last Visit ( LSLV ) ( Follow contact month 7-8 ) . - Study Groups : - PCV-free HRV liquid formulation lot A ( also refer Liq_A Group ) - PCV-free HRV liquid formulation lot B ( also refer Liq_B Group ) - PCV-free HRV liquid formulation lot C ( also refer Liq_C Group ) - GSK Biologicals ' currently license lyophilise HRV formulation ( also refer Lyo Group ) - Control : active control-GSK Biologicals ' currently license lyophilise HRV vaccine - Vaccination schedule : Two dos HRV vaccine administer accord 0 , 1-2 month schedule accord immunisation schedule RV vaccine .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) /LAR ( ) , opinion investigator comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) ( Legally acceptable representative ) subject prior performing study specific procedure . A male female infant , include , 6 12 week ( 4290 day ) age time first study vaccination . Born fullterm ( i.e. , gestation period 37 week 0 day 41 week 6 day ) . Healthy subject establish medical history clinical examination enter study . Child care Use investigational nonregistered product study vaccine period start 30 day first dose study vaccine ( Day29 Day 0 ) , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . For corticosteroid , mean prednisone ( 0.5 mg/kg/day , equivalent ) . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration longacting immunemodifying drug time study period . Planned administration/administration vaccine foreseen study protocol period start 30 day first dose vaccine administration end Visit 3 , exception inactivate influenza vaccine , allow time study license routine childhood vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Uncorrected congenital malformation gastrointestinal tract would predispose Intussusception ( IS ) . History IS . Family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Major congenital defect serious chronic illness . Previous vaccination RV . Previous confirm occurrence RVGE . GE within 7 day precede study vaccine administration . History reaction hypersensitivity likely exacerbate component vaccine . Hypersensitivity latex . Acute disease and/or fever time enrolment . Fever define temperature ≥38.0°C/100.4°F . The preferred location measure temperature study oral cavity , axilla rectum . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Healthy infant</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Human Rotavirus ( HRV )</keyword>
</DOC>